Table 1 Demographic and clinical data of patients guided with the pp65 antigenemia assay or with a real-time PCR assay
Parameter | No. of patients (%) | P-valuea | |
|---|---|---|---|
AG guidance | QRT–PCR guidance | ||
Patients, no. | 90 | 57 | |
Median age, years (range) | 49 (18–70) | 48 (15–71) | |
Sex | |||
Male | 53 (59) | 35 (61) | |
Female | 37 (41) | 22 (39) | 0.863 |
Underlying disease | |||
Acute lymphatic leukemia | 8 (9) | 6 (10) | |
AML | 34 (38) | 26 (46) | |
Aplastic anemia | 1 (1) | 1 (2) | |
Chronic lymphatic leukemia | 2 (2) | 5 (9) | |
CML | 5 (6) | 0 | |
Hodgkin disease | 4 (5) | 3 (5) | |
Multiple myeloma | 5 (6) | 2 (3) | |
Myelodysplastic syndrome | 3 (3) | 1 (2) | |
Myelofibrosis | 4 (4) | 0 | |
Non-Hodgkin lymphoma | 21 (23) | 12 (21) | |
Plasma cell leukemia | 1 (1) | 1 (2) | |
Others | 2 (2) | 0 | 0.313 |
Stem cell source | |||
BM | 1 (1) | 1 (2) | |
Peripheral blood | 70 (78) | 40 (70) | |
Cord blood | 19 (21) | 16 (28) | 0.581 |
Type of donor | |||
Related | 42 (47) | 25 (44) | |
Unrelated | 48 (53) | 32 (56) | 0.865 |
HLA match | |||
Identical | 69 (77) | 37 (65) | |
Mismatched | 21 (23) | 20 (35) | 0.135 |
CMV serostatus | |||
D−/R− | 8 (9) | 9 (16) | |
D−/R+ | 31 (34) | 20 (35) | |
D+/R− | 5 (6) | 4 (7) | |
D+/R+ | 46 (51) | 24 (42) | 0.540 |
Conditioning regimen | |||
Non-myeloablative | 56 (62) | 29 (51) | |
Myeloabalative | 34 (38) | 28 (49) | 0.230 |
Acute GVHD | |||
Grades 0-I | 57 (63) | 29 (54) | |
Grades II-IV | 33 (37) | 25 (46) | 0.211 |
